Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Probiotics for RBD in Parkinson's Disease
NCT06710574Phase 4Recruiting
- Sponsor
- Beijing Friendship Hospital
- Start
- Sep 2022
- Primary completion
- Jun 2025
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 4, open-label trial of bifidobacterium triple viable and bacillus licheniformis in rapid eye movement sleep behavior disorder (RBD) (4 arms), sponsored by Beijing Friendship Hospital. Primary endpoints: Magnetic resonance imaging changes of brain structure and function at 12 weeks, Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale at 12 weeks and 1 more. Started Sep 2022; status: recruiting.
02
Drugs
bifidobacterium triple viablebacillus licheniformis
03
Conditions
rapid eye movement sleep behavior disorder (RBD)
Beyond the preview
Go deeper on NCT06710574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06710574.